Needham has upgraded Penumbra Inc (PEN) from Hold to Buy, signaling a more favorable outlook on the company’s future. The action, taken on October 7, 2025, comes as Penumbra's current stock price stands at $291.89.
This upgrade reflects an improved sentiment regarding Penumbra's fundamentals and overall business performance. The company's innovative medical products, aimed at treating conditions such as Pulmonary Embolism and Deep Vein Thrombosis, continue to drive its growth. Headquartered in Alameda, California, Penumbra employs approximately 4,500 people and boasts a market capitalization of $11.0 billion, with a trailing P/E ratio of 66.86 and an EPS of 4.14.
Looking ahead, Penumbra Inc is scheduled to report its upcoming earnings on July 27, 2026, with an estimated EPS of $1.21 and revenue expectations of $391.3 million. This follows a series of positive earnings surprises in recent quarters, including a notable 23.9% surprise in Q1 2025.
Analyst ratings can provide valuable insights, but they are based on specific assumptions and projections that may not always materialize. As such, investors are encouraged to consider a range of factors, including company fundamentals and industry trends, in their decision-making processes. Notably, the current analyst consensus for Penumbra is classified as Buy, with 8 Strong Buy, 12 Buy, and 4 Hold ratings among 24 analysts surveyed as of November 1, 2025.